CRISPR Therapeutics AG (NASDAQ:CRSP) is among the top 10 stocks to buy from Cathie Wood’s stock portfolio. CRISPR made up roughly 3.8% of ARK Investment’s disclosed equity portfolio at ...
CorriXR Therapeutics announced new peer-reviewed findings showing that its CRISPR-based gene-editing approach can resensitize squamous cell lung carcinoma (LUSC) tumors to standard chemotherapy, ...
TriLink BioTechnologies senior scientist Dr Cody Palumbo discusses the blockers to manufacturing mRNA-based gene editing ...
In a major step forward for cancer care, researchers at ChristianaCare's Gene Editing Institute have shown that disabling the NRF2 gene with CRISPR technology can reverse chemotherapy resistance in ...
This article and associated images are based on a poster originally authored by Daniela Flehberger, Sofia Buianova, Emma Langguth, Johanna Irnstorfer, Stefanie Fellinger, Henrik Schmidt, Adam Krejci, ...
On Saturday, CRISPR Therapeutics AG (NASDAQ:CRSP) shared Phase 1 data from its ongoing clinical trial evaluating CTX310, an investigational, in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3.
This valuable work investigates the role of protein N-glycosylation in regulating T-cell activation and function and suggests that B4GALT1 is a potential target for tumor immunotherapy. The strength ...
Not revised: This Reviewed Preprint includes the authors’ original preprint (without revision), an eLife assessment, public reviews, and a provisional response from the authors. The study by Yu et al ...
-Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback